June 04, 2021
Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
June 03, 2021
Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference
June 01, 2021
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
We champion an approach that views patients holistically and with compassion. Working together with stakeholders across the healthcare community, our team is focused on cutting-edge science, developing innovative medicines and patient-focused advocacy to make a real-world impact in the lives of people living with difficult-to-treat conditions.
Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.
In response to urgent and unexpected needs created by the COVID-19 pandemic, Alkermes acted quickly to prioritize the safety of our employees and our communities, and adapted our business practices to support uninterrupted supply of, and patient and provider access to, our medicines and development products.
LYBALVI™ (olanzapine and samidorphan) - Schizophrenia/Bipolar I Disorder
ALKS 1140 - Neurology (Orphan)